Publication: EGFL7 and RASSF1 promoter hypermethylation in epithelial ovarian cancer
3
Issued Date
2018-08-01
Resource Type
ISSN
22107770
22107762
22107762
Other identifier(s)
2-s2.0-85046404105
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancer Genetics. Vol.224-225, (2018), 37-40
Suggested Citation
Yanisa Rattanapan, Veerawat Korkiatsakul, Adcharee Kongruang, Takol Chareonsirisuthigul, Budsaba Rerkamnuaychoke, Anna Wongkularb, Sarikapan Wilailak EGFL7 and RASSF1 promoter hypermethylation in epithelial ovarian cancer. Cancer Genetics. Vol.224-225, (2018), 37-40. doi:10.1016/j.cancergen.2018.04.117 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/45086
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
EGFL7 and RASSF1 promoter hypermethylation in epithelial ovarian cancer
Other Contributor(s)
Abstract
© 2018 Elsevier Inc. DNA methylation is one of the epigenetic mechanisms associated with gene expression and plays a key role as in activation and deactivation of oncogenes and tumor suppressor genes, respectively. This study employed DNA methylation array to identify methylated genes which are highly correlated with various phenotypes of epithelial ovarian cancer (EOC) in Thai patients and to quantify promoter CpG-island methylation of candidate genes. Tissues from patients with serous and non-serous EOC showed significantly higher promoter methylation of EGFL7 and RASSF1 compared to benign cases. These results indicate the potential of investigating promoter CpG-island methylation of cancer-associated genes as biomarkers of disease progression and even possibly of early detection.